Hypolipidemic effect of β,β'-methyl-substituted hexadecanedioic acid (MEDICA 16) in normal and nephrotic rats

J. Bar-Tana, G. Rose-Kahn, B. Frenkel, Z. Shafer, M. Fainaru

Research output: Contribution to journalArticlepeer-review

Abstract

Treatment of normal or puromycin aminonucleoside-nephrotic rats, kept on a balanced Purina chow diet, with β,β'-tetramethyl-substituted hexadecanedioic acid (MEDICA 16) (Bar-Tana, J., G. Rose-Kahn, and M. Srebnik. 1985. J. Biol. Chem. 260: 8404-8410) resulted in an acute reversible inhibition of liver lipogenesis and cholesterogenesis with a concomitant hypolipidemic effect which was sustained as long as the drug was administered. The hypolipidemic effect in normal and nephrotic rats consisted of 70-80% and 40-60% reduction in plasma VLDL-triacylglycerols and cholesterol, respectively, with a respective increase in the HDL-cholesterol/(VLDL + LDL)-cholesterol ratio. The observed hypolipidemic effect was accompanied by a 10-fold decrease in VLDL-apoC-III content with a concomitant enrichment of the VLDL fraction by VLDL remnants having an increased apoB-100/apoB-48 ratio. The pharmacological reduction of VLDL by MEDICA 16 may offer a treatment mode of choice for selected hyperlipidemic states.

Original languageEnglish
Pages (from-to)431-441
Number of pages11
JournalJournal of Lipid Research
Volume29
Issue number4
StatePublished - 1988
Externally publishedYes

Fingerprint

Dive into the research topics of 'Hypolipidemic effect of β,β'-methyl-substituted hexadecanedioic acid (MEDICA 16) in normal and nephrotic rats'. Together they form a unique fingerprint.

Cite this